Bristol Myers Squibb acquires Nvidia's Vera Rubin DGX SuperPOD for drug discovery, becoming the first pharma company to deploy the latest AI computing

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

Bristol Myers Squibb is the third drugmaker in nine months to announce it is building the largest AI supercomputer in the life sciences industry.